Actos Bladder Cancer Allegations Attorney Alert: Resource4thePeople Announces Continuation of Free Consultations for Consumers in 2014

Share Article

National network of attorneys will resume availability in connection with consumer inquiries over allegations that the use of the diabetes medication Actos can cause patients to develop bladder cancer.

Resource4thePeople today announced today that its national network of attorneys will continue to offer no-cost consultations in 2014 to consumers who are seeking compensation involving allegations contained in lawsuits* that the use of Actos to treat diabetes can cause bladder cancer.

“We are proud to announce that our policy of providing these consultations to consumers inquiring about bladder cancer allegations contained in these numerous federal lawsuits and the legal options that may be available to them to seek compensation will be resumed in 2014,” said Resource4thePeople.

The announcement was made after numerous inquiries were received from consumers about whether the Resource4thePeople national network of attorneys would, after 2013, continue to offer these consultations involving bladder cancer concerns raised in these lawsuits and in a Food and Drug Administration safety announcement,** said Resource4thePeople.

“The continued increase in the number of consumers inquiring about alleged Actos side effects since the FDA issued its health advisor over bladder cancer concerns shows that there are a great number of affected consumers seeking experienced, aggressive legal help,” said Resource4thePeople.

Concerns about Actos were raised in the June 15, 2011 FDA safety announcement after the agency reviewed a study sponsored by Actos manufacturer Takeda Pharmaceuticals which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.

Here is part of the safety announcement:

“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.”

Resource4thePeople also announced that it will continue to update consumers about the latest developments in litigation involving these allegations.

Among the most recent developments is the increase in Actos lawsuits* from across the country making these allegations that have been consolidated before a federal judge in the Western District of Louisiana.

The number of cases is now over 2,600, according to recent figures compiled by the U.S. Judicial Panel on Multidistrict Litigation.*** The panel assigned the lawsuits from jurisdictions across the country to the Louisiana judge because they share common claims against a common defendant.

Judge Rebecca F. Doherty has scheduled the first bellwether trial from that litigation for early this year, according to the court file.

“The first bellwether trial in that litigation will be held after two other trials in 2013 in which juries returned verdicts against Takeda Pharmaceuticals involving allegations that the medication can lead to bladder cancer in patients new lawsuits continue to be filed,” said Resource4thePeople.

“Even though those verdicts were set aside over legal technicalities we note an increase in the number of consumer inquiries over these allegations and the continuation of the filing of lawsuits involving bladder cancer allegations linked to the use of Actos.”

Among the most recent lawsuits filed are four filed by men in Illinois.**** Each man is seeking over $1.75 million in damages over allegations that their treatment with Actos caused them to develop bladder cancer.

The cases were filed in the wake of a Maryland jury's award***** of $1.7 million to the family of a man who alleged that his use of Actos caused him to die of bladder cancer. That verdict was overturned after the judge found that the victim’s 30-year smoking habit contributed to his death.

The Maryland case was the second this year in which a jury found in favor of a plaintiff alleging that Takeda Pharmaceuticals was liable over bladder cancer but had the damages overturned on legal technicalities, according to court documents.

The Maryland case was preceded by one in California where a jury found in April that Takeda should pay $6.5 million in damages over similar allegations, according to the court file in that case.******

"In two cases involving serious allegations that Takeda failed to properly warn patients and doctors about the drug’s links to bladder cancer juries have returned verdicts in favor of the victims," said Resource4thePeople.

Bloomberg News reported Sept. 26, 2013 that Takeda Pharmaceuticals, which is Asia's largest drug manufacturer, has been named in "more than 3,000 suits over the drug."*******

The Bloomberg News report cited important facts about the Maryland case:

"A Maryland jury ruled that Takeda Pharmaceutical Co. (4502) didn’t properly warn an ex-U.S. Army translator and his doctor about the risks of its Actos diabetes drug and ordered the company to pay more than $1.7 million in damages. A judge immediately threw out the verdict.

"Jurors in state court in Baltimore deliberated more than six hours over two days before finding Asia’s largest drugmaker liable for the cancer death of Diep An, Michael Miller, one of An’s lawyers, said in an interview. Since jurors also found that An contributed to his death by smoking for 30 years, Judge Brooke Murdock set the verdict aside based on Maryland law."

*In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana
****Allen et. al v. Takeda Pharmaceuticals North America, Case # 12cv0064, U.S. District Court for the Western District of Louisiana.
*****Case #s 13-536 – 13-539, Madison County Circuit Court of Illinois
******An v. Nieberlein, Case # 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland
*******Cooper v. Takeda Pharmaceuticals America Inc., Case #CGC-12-518535, California Superior Court, Los Angeles

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bill Callahan
+1 858 602-2749
Email >
Visit website